GOVERNMENT OF THE PEOPLE'S REPUBLIC OF BANGLADESH
MINISTRY OF HEALTH & FAMILY WELFARE
DIRECTORATE GENERAL OF DRUG ADMINISTRATION
OUSHAD BHABAN, MOHAKHALI
DHAKA-1212, BANGLADESH
www.dgda.gov.bd

CERTIFICATE OF GOOD MANUFACTURING PRACTICE (GMP) FOR PHARMACEUTICAL (PRODUCTS)

This certificate conforms to the format recommended by the World Health Organization (WHO)

Certificate Number: DGDA/6-91/04/ 10638 **Date:** 24-07-2025

It is hereby certified that M/s. **Incepta Pharmaceuticals Ltd.**, a drug (Pharmaceutical Products) manufacturing and marketing organization, has been given license to manufacture and sell its products freely in the People's Republic of Bangladesh as lawfully required and granted in pursuance of the provision of chapter-vii, of The DRUGS AND COSMETICS ACT, 2023 (ACT NO. XXIX of 2023) or any Rule made there under.

On the basis of inspection carried out on 29-04-2025 & 07-07-2025 we certify that the site indicated on this certificate complies with Good Manufacturing Practices for the dosage forms, categories and activities listed in Table 1.

1. Name & Address of Site: **Incepta Pharmaceuticals Ltd.**
   Dewan Idris Road, Bara Rangamatia, Zirabo, Ashulia, Savar, Dhaka-1341, Bangladesh
2. Manufacturer's License No.: Non-Biological-193 Date of Issue: 27-06-1967
   Biological-108 Date of Issue: 27-06-1989
3. Table: 1

Dosage Form(s)	Category(ies)	Activity(ies)
Tablet (Uncoated, Coated, Delayed-Release, Extended-Release, Controlled Release, Modified Release, Sublingual, Buccal, Chewable, Effervescent, Orodispersible, MUPS, Vaginal Tablets), Hard Capsule (Powder Filled, Pellet Filled, Liquid Filled), Sachet (Powders, Coated Granules), Oral Drops, Powder for Oral Drops, Nasal Drops, Eye Drops (Solution, Suspension, Emulsion), Ear Drops (Solution, Suspension, Emulsion), Nasal Sprays (Solution, Suspension), Syrup, Injectables (Injections – Intravenous, Intramuscular, Subcutaneous, Intra-Articular, Lyophilized, Powder, Intravenous Infusions),	Antibiotics [Cephalosporins; Beta-lactam (except Cephalosporins); Non Beta-lactam], Antihypertensive and Cardioprotectives, Analgesics and Antipyretics, Steroids, Antidiarrhoeal, Antacids and Antiulcerants, Hematinics, Vitamins and Minerals, Antifungals, Antidiabetics, Anthelmintics, Antiamebics, Antiemetics, Laxatives, Antispasmodics, Antihistamines and Antiallergics, Expectorants, Antiasthmatics and Bronchodilators, Anxiolytics, Antidepressants, Antimigraine, Nutrient supplements, Gynaecological drugs, Antipsychotic, Anti-Inflamatory, Opthalmics, Antiepileptics, Anticonvulsants, Anticoagulants, Antiplatelets, Diuretics, Insulins, Lipid-lowering Agents, Medication for Hepatitis B and C, Antivirals,	• Procurement of Starting and Packaging Materials from Approved Sources • Quarantine of Starting and Packaging Materials in Warehouse • Sampling and Testing of Starting and Packaging Materials • Storage of Released Starting and Packaging Materials • Dispensing of Starting and Packaging Materials • Control of Manufacturing Environment • Manufacturing of Finished Products and Biotherapeutic Drug Substances • In Process Control of Intermediates, Bulks and Finished Products and Biotherapeutic Drug Substances

Continued to Page-2

MINISTRY OF HEALTH & FAMILY WELFARE ★ DIRECTORATE GENERAL OF DRUG ADMINISTRATION ★ GOVT. OF THE PEOPLE'S REPUBLIC OF BANGLADESH ★ DHAKA

Dosage Form(s)	Category(ies)	Activity(ies)
Oral Solution, Powder for Oral solution, Nebulizer Solution, Nebulizer Suspension, Oral Suspension, Oral Emulsion, Powder for Oral Suspension, Elixir, Respiratory Solution, Dry Powder for Inhalation, Biotherapeutic Drug Product, Biotherapeutic Drug Substance	Immunosuppressants, Anesthetics, Antifibrinolytics, Antimalarial, Tinibs, Monoclonal Antibody (mAbs), Cytokines, Hematopoietic Agents, Antigout, Urologicals, Tyrosine Kinase Inhibitors, CDK 4/6 Inhibitor, Antirheumatic.	• Control of Packaging and Labeling • Quality Assurance of Finished Product and Biotherapeutic Drug Substances • Storage of Finished Products • Effluent Treatment and Safe Disposal of Pharmaceutical Wastes • Stability Studies

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

The manufacturing plant in which the pharmaceutical products are produced is subject to inspection at suitable intervals.

The manufacturer conforms to the requirements for good practices in the manufacture and quality control (GMP) of drugs, as required under law in this country, as well as recommended by the **World Health Organization (WHO)** in respect of pharmaceutical products to be manufactured, sold or distributed within the country of origin or to be exported.

This certificate remains valid for a period of 2 (Two) years from the date of issue. It becomes invalid if the activities and/or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Name of Authorized Person : **Major General Md. Shameem Haidar**
Address of the Certifying Authority : **Directorate General of Drug Administration**
Mohakhali, Dhaka-1212
Telephone : +880-(0)2-2222-80803
Fax No : +880-(0)2-9880854
E-mail : dgda.gov@gmail.com
Web-site : www.dgda.gov.bd

Stamp and Date:

MINISTRY OF HEALTH & FAMILY WELFARE ★ DIRECTORATE GENERAL OF DRUG ADMINISTRATION ★ GOVT. OF THE PEOPLE'S REPUBLIC OF BANGLADESH
DHAKA

Major General Md. Shameem Haidar
Director General
Directorate General of Drug Administration
&
Licensing Authority (Drugs)
Govt. of the People's Republic of Bangladesh

23 JUL 2025

ANNEXURE - I

Annexure to the Non-Biological drug manufacturing licence No.193 of M/S INCEPTA Pharmaceuticals Ltd., Savar, Dhaka, Bangladesh.

DAR No.	Product Name	Composition	Speci-fication	Qty./Tablet (in mg)
116-1149-072		**Active Ingredient (s)**		
	Aldocort Tablet (20, 30, 50, 100 tablets in blister/strip pack)	Fludrocortisone Acetate	USP	0.1000
		Excipients		
		Microcrystalline Cellulose (Avicel 102)	BP/Ph. Eur.	31.5100
		Lactose /Lactose Monohydrate (Fine)	BP/Ph. Eur.	31.2000
		Croscarmellose Sodium	BP/Ph. Eur.	1.3000
		Quinolone Yellow Lake	In-house	0.0350
		Magnesium Stearate	BP/Ph. Eur.	0.8500

Inclusion Date : 04-12-2016

Valid Up to : 03-12-2026

MINISTRY OF HEALTH & FAMILY WELFARE ★ DIRECTORATE GENERAL OF DRUG ADMINISTRATION ★ GOVT. OF THE PEOPLE'S REPUBLIC OF BANGLADESH
DHAKA

Major General Mohammad Yousuf
Director General
Directorate General of Drug Administration
&
Licensing Authority (Drugs)
Govt. of the People's Republic of Bangladesh

20 APR 2022